| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_02ad4c9403364a2277dc906d5bc5642e |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2123-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F5-003
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-103 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F5-00 |
| filingDate |
2020-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5b6917cd7c519520e71a97175167f5da
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f5595c35ae59d3ea618a0963c411dea3 |
| publicationDate |
2021-06-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20210068973-A |
| titleOfInvention |
Novel gadolinium-based compound, pharmaceutical composition for treating or preventing inflammatory disease comprising the same, and mri contrast composition |
| abstract |
The present invention relates to a gadolinium-based compound represented by the following formula (1). [Formula 1] In Formula 1, RosA is a moiety derived from rosmarinic acid. The compound according to the present invention may be used in a composition for treating or preventing an inflammatory disease and/or an MRI contrast composition for diagnosing an inflammatory disease or a degenerative brain disease. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023003411-A1 |
| priorityDate |
2019-12-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |